These products are used in direct response to the covid-19 pandemic.
The COVID-19 outbreak has resulted in an urgent need for medical products and solutions. In response, Sinoscience has expanded our production into coronavirus related products, including the VTM tube, nucleic acid extraction reagent and extractor and so on.
Covid-19 Medical Products,Vtm Test Kit,Vtm Transport Tube Kit,Vtm Specimen Tube Kit Jilin Sinoscience Technology Co. LTD , https://www.contoryinstruments.com
New tetravalent influenza vaccine is expected to be listed this year
On March 27, the reporter learned from the press conference of the Ministry of Science and Technology and the National Health and Health Committee on the major results of infectious disease prevention and control technology. In response to major outbreaks, China has realized “from passive response to active responseâ€. The transformation. At the same time, the new four-valent influenza vaccine has been submitted for approval and is expected to be listed this year.
Liu Dengfeng, director of the special implementation management office and the ombudsman of the Department of Science and Education of the National Health and Health Committee, said that the special project has played an important supporting role in effectively responding to major outbreaks such as influenza A (H1N1), H7N9, Middle East respiratory syndrome and Ebola in recent years. The transition from passive response to epidemic to active response to threats has been achieved.
The past 2017 winter flu is still fresh in my memory. Under the special support, by monitoring the seasonal influenza influenza intensity and virus variation, it provides a scientific basis for the prevention and control of influenza in winter in China. Xu Jianguo, deputy chief engineer of the special technology and academician of the Chinese Academy of Engineering, said, "Although we have made great progress, we have not recognized all the problems of the flu, and there are still many scientific questions to be answered."
"The new four-valent influenza vaccine has been submitted for approval and is expected to be listed this year." Xu Jianguo said that the next step will be to strengthen the research on emergency treatment technology and continuously improve the clinical treatment capacity of severe influenza cases.
Li Lanjuan, deputy general manager of special technology and academician of Chinese Academy of Engineering, led the team to establish an early rapid identification system for new infectious disease pathogens with special support. Through advanced technologies such as sequencing and high-throughput analysis, the monitoring and control of infectious disease prevention and control across the country was And put forward the "four anti-two balance" therapy, and innovated the rescue strategy.
"With the support of special projects, the ability and level of influenza vaccine development in China has increased significantly. Once the influenza virus has new variations, we can actively develop influenza vaccines and take the initiative in our hands." Li Lanjuan said.
The National Science and Technology Major Project of the Ministry of Science and Technology is an important starting point for implementing the innovation-driven development strategy, aiming at major strategic needs and making significant progress. Yang Zhe, deputy director of the major special affairs office of the Ministry of Science and Technology, said that in the process of organizing the implementation of infectious disease prevention and control, a large number of major landmark achievements have been produced. In recent years, major prevention and control of major epidemics have successfully responded and taken the initiative to improve the people and improve the technology. People's livelihood provides a strong guarantee.